Although some scholars have shown that intravitreal injection of VEGF inhibitors may reduce the serum VEGF in patients with ROP, the BEAT-ROP trial found that VEGF inhibitors do not increase the mortality of children [18]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.